Observational Study of Antipsychotic Medication Use

RE-KINECT was a prospective, real-world, observational, multicenter study conducted at 37 outpatient psychiatry clinics (e.g., research institutions, community health centers, private practices) in the United States from April 2017 to January 2018 [17 (link)]. In brief, this study included adults with ≥ 3 months of lifetime exposure to antipsychotic medication and ≥ 1 clinician-confirmed psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria [19 ]. The 3 month lifetime antipsychotic exposure requirement was based on the Schooler-Kane criteria for TD research and DSM-IV-TR [20 (link), 21 ], and it is consistent with current American Psychiatric Association guidelines (DSM-5-TR) [22 ]. All patients provided written informed consent prior to participation; Institutional Review Board approval was obtained at each site.